Skip to main content
SpringerLink
Log in

Nebenwirkungsprofil einer frühen Immuntherapie nach Radiotherapie: eine gepoolte Analyse von Studien in der Datenbank der US Food and Drug Administration

Side effect profile of early immunotherapy after radiotherapy: a pooled analysis of studies in the US Food and Drug Administration database

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Verma V, Cushman TR, Tang C, Welsh JW (2018) Toxicity of radiation and immunotherapy combinations. Adv Radiat Oncol 3(4):506–511

    Article  Google Scholar 

  2. Martin AM, Cagney DN, Catalano PJ, Alexander BM, Redig AJ, Schoenfeld JD, Aizer AA (2018) Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation. JAMA Oncol 4(8):1123–1124

    Article  Google Scholar 

  3. Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895–903

    Article  CAS  Google Scholar 

  4. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929

    Article  CAS  Google Scholar 

  5. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M, CheckMate 577 Investigators (2021) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384(13):1191–1203

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Strahlentherapie-Radioonkologie, Medizinische Universität Graz, Auenbruggerplatz 32, 8036, Graz, Österreich

    Lukas Seiß &  Thomas Brunner

Authors
  1. Lukas Seiß
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Brunner.

Ethics declarations

Interessenkonflikt

L. Seiß und T. Brunner geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seiß, L., Brunner, T. Nebenwirkungsprofil einer frühen Immuntherapie nach Radiotherapie: eine gepoolte Analyse von Studien in der Datenbank der US Food and Drug Administration. Strahlenther Onkol 198, 1049–1051 (2022). https://doi.org/10.1007/s00066-022-01995-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-022-01995-2

Search

Navigation